Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alfasigma S.p.A.
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
The FDA required an updated REMS for liver monitoring out of caution over potential liver toxicity, though the drug has not caused drug-induced liver injury in development to date.
Private Company Edition: Acelyrin will use its latest funding for Phase III development of izokibep in inflammatory diseases. Also, ArsenalBio raised $220m to take its programmable cell therapies into the clinic and RayzeBio’s $160m series D round will fund clinical trials for its radiopharmaceuticals.
Phase II data position cemdisiran well for Phase III, but several agents are already well ahead. However, Alnylam foresees a polypharmacy approach.
- Other Names / Subsidiaries
- Defiante Farmaceutica S.A.
- Sigma-Tau Pharma Ltd
- Sigma-Tau Arzneimittel GmbH
- Sigma-Tau Research Switzerland SA
- Biofutura Pharma S.p.A.
- Alfa Wassermann SpA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.